invivopartners

Invivo Establishes Scientific Advisory Board to Support Its Latest Fund

Advisory Board Assembles a Distinguished Panel of Experts in Synthetic Biology, AI, and Advanced Therapies

Barcelona, 27th March 2025 – Invivo Ventures III, the latest life sciences and healthcare investment fund from Invivo Partners, proudly announces the formation of its **Scientific Advisory Board (SAB)**. This distinguished panel brings together **world-class expertise in synthetic biology, RNA therapeutics, cell and gene therapy, artificial intelligence (AI), and business development**—reflecting the fund's commitment to investing in groundbreaking biotech innovations.

The five members of the SAB offer **complementary skill sets** spanning key areas of **biotechnology, computational sciences, and commercialization strategies**, ensuring a multi-disciplinary approach to evaluating and supporting portfolio companies:

- **Luis Serrano, Ph.D. -** Director of the Centre for Genomic Regulation (CRG), Dr. Serrano is a leading expert in synthetic biology and systems biology. With a career spanning EMBL Heidelberg and CRG Barcelona, he has contributed to advancements in protein folding, computational biology, and genetic engineering. He has been recognized with prestigious awards, including the Marie Curie Excellence Award, three ERC Advanced Grants, and has played a pivotal role in technology transfer initiatives.
- **Begoña Carreño, Ph.D.**– A leading biopharma executive with deep experience in drug development, Dr. Carreño is currently the Chief Business Development Officer Aspeya, (formerly known as Vectura Fertin Pharma) in Switzerland. She has led business development and licensing (BD&L) efforts at Novartis and Almirall across multiple therapeutic areas, including respiratory, cardiovascular, and musculoskeletal diseases, with a strong track record in M&A and licensing deals.
- **Pep Martorell, Ph.D.**– Associate Director of the Barcelona Supercomputing Center (BSC), Dr. Martorell has extensive experience in scientific management, technology transfer, and entrepreneurship. Formerly the Director-General of Research for the Government of Catalonia, he has played a pivotal role in supporting tech-driven startups in Barcelona.
- **Theresa Heggie** – With a distinguished career in gene and RNA therapies, Ms. Heggie has led global commercial strategy and operations, business development, and market access strategies. She has worked at Alnylam Pharmaceuticals (RNAi therapies), Shire Human Genetic Therapies, and Freeline Therapeutics (gene therapy). She has board-level experience in biotech growth and corporate strategy, ensuring that novel therapies successfully reach the market and patients.
- **Timothy Lu, M.D., Ph.D.**– A pioneer in synthetic biology and biopharmaceutical innovation, Dr. Lu is CEO of Senti Biosciences and Associate Professor at MIT, where he has led the development of programmable gene circuits and engineered cell therapies. He co-founded multiple biotech ventures, including Synlogic, Eligo Bioscience, and BiomX, and has received the NIH New Innovator Award and MIT Technology Review's TR35, among other awards. His expertise bridges cell and gene therapies with computational biology.

Bridging Cutting-Edge Science with Investment Strategy
Invivo Ventures III focuses on early-stage biotech investments, leveraging the SAB's collective knowledge in biotechnology, AI-driven drug discovery, advanced therapies, synthetic biology, and market strategy to identify high-potential opportunities.

“The convergence of synthetic biology, AI, and advanced therapies is shaping the future of medicine,” said Dr. Luis Pareras, Managing Partner at INVIVO PARTNERS. “By assembling a Scientific Advisory Board with such diverse expertise, we ensure that our investment decisions are informed by the latest scientific advancements and commercial insights.”

About INVIVO PARTNERS

Invivo Partners is a venture capital firm specializing in early-stage life sciences companies. It is managed by Luis Pareras, Albert Ferrer, and Laura Rodríguez, with investments in 16 companies and three funds under management. The firm recently announced its third fund, targeting €100 million for investments in early-stage life science companies at the intersection of advanced therapies, synthetic biology, and artificial intelligence. Invivo Ventures III has a majority of private investors with the support of a number of institutional investors such as the European Investment Fund (EIF), Fond-ICO Next Tech, the Catalan Finance Institute and the Barcelona City Council. More information: https://invivo.partners/